Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amylyx PharmaceuticalsAMLX -0.66%33 12-1 Month Momentum % is 132.59% as of Aug. 11, 2026. GuruFocus rates AMLX with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 1,016 Drug Manufacturers companies, Amylyx Pharmaceuticals ranks better than 96.16% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-11), Amylyx Pharmaceuticals's 12-1 Month Momentum % is 132.59%.
The industry rank for Amylyx Pharmaceuticals's 12-1 Month Momentum % or its related term are showing as below:
AMLX's 12-1 Month Momentum % is ranked better than 96.16% of 1016
companies
in the Drug Manufacturers industry
Industry Median: -12.29
vs AMLX: 132.59
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Amylyx Pharmaceuticals 12-1 Month Momentum % Related Terms
AMLX vs ANIP, PBH, BCRX: 12-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amylyx Pharmaceuticals's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amylyx Pharmaceuticals 12-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amylyx Pharmaceuticals's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Amylyx Pharmaceuticals's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 12-1 Month Momentum % of 132.59% mean?
Amylyx Pharmaceuticals (AMLX) has a 12-1 Month Momentum % of 132.59% as of Aug. 11, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Amylyx Pharmaceuticals and its competitors. According to the industry distribution chart, Amylyx Pharmaceuticals ranks #39 out of 1016 companies in the Drug Manufacturers industry, placing it in the top 3.8%.
Is Amylyx Pharmaceuticals' 12-1 Month Momentum % too high?
Amylyx Pharmaceuticals' current 12-1 Month Momentum % is 132.59%. Based on the distribution chart, Amylyx Pharmaceuticals ranks #39 out of 1016 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Amylyx Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Amylyx Pharmaceuticals' 12-1 Month Momentum % compare to ANIP and PBH?
According to the Drug Manufacturers industry distribution chart, Amylyx Pharmaceuticals ranks #39 out of 1016 companies for 12-1 Month Momentum %. This places Amylyx Pharmaceuticals in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Drug Manufacturers company?
A good 12-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Amylyx Pharmaceuticals and its competitors. Amylyx Pharmaceuticals's current 12-1 Month Momentum % is 132.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amylyx Pharmaceuticals stock overvalued right now?
Amylyx Pharmaceuticals (AMLX) has a current 12-1 Month Momentum % of 132.59%. The current 12-1 Month Momentum % is 132.59%. Amylyx Pharmaceuticals' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Amylyx Pharmaceuticals (AMLX), the current 12-1 Month Momentum % is 132.59% as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
33GF Score
Get the complete analysis for AMLX
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMLX has been successfully added to your 
